Get the Stockscreener App
7.89
3.68%
0.28
Engene Therapeutics Inc stock is traded at $7.89, with a volume of 426.27K.
It is up +3.68% in the last 24 hours and up +17.94% over the past month.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
See More
Previous Close:
$7.61
Open:
$7.72
24h Volume:
426.27K
Relative Volume:
1.07
Market Cap:
$528.55M
Revenue:
-
Net Income/Loss:
$-122.44M
P/E Ratio:
-3.5004
EPS:
-2.254
Net Cash Flow:
$-103.79M
1W Performance:
+13.36%
1M Performance:
+17.94%
6M Performance:
+24.45%
1Y Performance:
+114.40%
1-Day Range:
$7.485
$8.03
1-Week Range:
$6.86
$8.03
52-Week Range:
$2.65
$12.25
Engene Therapeutics Inc Stock (ENGN) Company Profile
Name
Engene Therapeutics Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Therapeutics Inc
|
7.89 | 528.55M | 0 | -122.44M | -103.79M | -2.254 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Engene Therapeutics Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | WBB Securities | Buy |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Nov-11-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Therapeutics Inc Stock (ENGN) Latest News
Invus-group and Avicenna report 6.7% and 1.1% stakes in enGene (ENGN) - Stock Titan
Piper Sandler reiterates Engene stock rating on clinical data outlook - Investing.com
Piper Sandler Maintains EnGene Therapeutics(ENGN.US) With Buy Rating, Maintains Target Price $26 - Moomoo
enGene Holdings Inc. (NASDAQ:ENGN) Sees Significant Increase in Short Interest - MarketBeat
H.C. Wainwright Keeps Their Buy Rating on enGene Holdings (ENGN) - The Globe and Mail
H.C. Wainwright Maintains EnGene Therapeutics(ENGN.US) With Buy Rating, Maintains Target Price $25 - Moomoo
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc. - The National Law Review
ENGN | enGene Therapeutics Inc. Common Insider Trading - Quiver Quantitative
WBB Securities initiates coverage of Engene Therapeutics (ENGN) with buy recommendation - MSN
Is enGene (ENGNW) stock facing uncertainty (-5.10%) 2026-04-20Trending Social Stocks - Newser
Wall Street Zen Downgrades enGene (NASDAQ:ENGN) to Sell - MarketBeat
enGene Holdings Inc. (NASDAQ:ENGN) Sees Large Growth in Short Interest - MarketBeat
ENGN Options Volatility — NASDAQ:ENGN - TradingView
WBB Securities Initiates a Buy Rating on enGene Holdings (ENGN) - The Globe and Mail
WBB Securities Initiates EnGene Therapeutics(ENGN.US) With Buy Rating, Announces Target Price $21.5 - Moomoo
ENGN Options Chain — NASDAQ:ENGN - TradingView
Engene Therapeutics Inc. Live Share Prices and Trades. ENGNW.US Live Streaming Share Prices. - London South East
ENGN Initiates Coverage On enGene Therapeutics -- Rating Set to Buy - GuruFocus
Sentiment Watch: Is enGene Holdings Inc Equity Warrant stock a value trap2026 Major Catalysts & Weekly Stock Performance Updates - baoquankhu1.vn
WBB Securities Initiates Coverage on enGene (NASDAQ:ENGN) - MarketBeat
enGene Therapeutics (NASDAQ:ENGN) Stock, Unusual Options - Benzinga
Published on: 2026-04-13 18:10:23 - baoquankhu1.vn
Aug Opening: Will enGene Holdings Inc stock hit new highs in YEAR2026 Support & Resistance & Risk Managed Investment Signals - baoquankhu1.vn
Revenue Check: Is enGene Holdings Inc forming bullish engulfing patterns2026 Risk Factors & High Return Trade Guides - baoquankhu1.vn
EBIT per share of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
EBITDA margin % of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
enGene Therapeutics (FRA:S0N0) Cyclically Adjusted PS Ratio : (As of Apr. 16, 2026) - GuruFocus
Cash per share of enGene Therapeutics Inc. – FWB:S0N0 - TradingView
Total liabilities of enGene Therapeutics Inc. – FWB:S0N0 - TradingView
Total liabilities & shareholders' equities of enGene Therapeutics Inc. – FWB:S0N0 - TradingView — Track All Markets
enGene Therapeutics Inc.: Shareholders Board Members Managers and Company Profile | CA29286X1015 - marketscreener.com
S0N0: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc. Changes Name and Prepares for 2027 Commercial Launch of Detalimogene Voraplasmid for High-Risk NMIBC - Minichart
enGene Therapeutics Inc.: Fundamental Analysis and Financial Ratings | ENGN | CA29286X1015 - marketscreener.com
ENGN: Static price chart | enGene Therapeutics Inc. | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc.: Target Price Consensus and Analysts Recommendations | ENGN | CA29286X1015 - marketscreener.com
enGene Therapeutics Inc.: Financial Data Forecasts Estimates and Expectations | ENGN | CA29286X1015 - marketscreener.com
enGene Therapeutics Rebrands as Company Nears Commercialization - TipRanks
Detalimogene program drives enGene (ENGN) shift to Therapeutics focus - Stock Titan
Bull Run: What analysts say about enGene Holdings Inc Equity Warrant stockFed Meeting & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Chipmakers Recap: How does enGene Holdings Inc compare to its peers2026 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
ENGE HLDGNPV: Shareholders Board Members Managers and Company Profile | CA29286M1059 - marketscreener.com
Is enGene Holdings Inc benefiting from interest rate changes2026 Market Overview & Daily Entry Point Alerts - baoquankhu1.vn
ENGNW Stock Warrant Price and Chart — NASDAQ:ENGNW - TradingView — Track All Markets
Smart Money: Is enGene Holdings Inc Equity Warrant stock a value trapMarket Risk Report & Verified Momentum Stock Watchlist - baoquankhu1.vn
EnGene Holdings Inc. will Change its Name to enGene Therapeutics Inc - marketscreener.com
enGene Therapeutics Announces Name Change Ahead of Potential 2027 Approval - National Today
enGene Announces Name Change to enGene Therapeutics Inc. - PharmiWeb.com
enGene Rebrands as enGene Therapeutics Ahead of Potential 2027 Commercial Launch - TipRanks
enGene Holdings changes name to enGene Therapeutics - Investing.com
enGene announces name change to enGene Therapeutics - TipRanks
Engene Therapeutics Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):